BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  Q&A: MindMed’s Dan Karlin Discusses Phase II Win and the Therapeutic Potential of Psychedelics

  After reporting positive mid-stage results for its LSD-based therapy for generalized anxiety disorder, MindMed’s chief medical officer sat down with BioSpace to discuss the path forward.

  January 3, 2024

   · 

  4 min read

   · 

  Tyler Patchen
• 

  FDA

  FDA Approvals Jumped 50% in 2023 Dominated by Novel Drug Nods for Pfizer

  The regulator greenlit 55 new drugs last year, seven of which belonged to Pfizer, including an ulcerative colitis treatment and a migraine nasal spray—both acquired in multibillion-dollar buys.

  January 3, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  Boehringer Inks Potential $2B Deal with Ribo, Targets NASH-MASH with siRNA Therapies

  In a collaboration agreement announced Wednesday, Boehringer Ingelheim will gain access to Ribo’s platform to target hepatocytes with investigational siRNA therapies for nonalcoholic or metabolic dysfunction-associated steatohepatitis.

  January 3, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  The top life sciences startups to watch this year

  Greg Slabodkin, Heather McKenzie and Tyler Patchen discuss BioSpace’s tenth annual NextGen list of the hottest new life sciences companies.

  January 3, 2024

   · 

  1 min read

   · 

  Greg Slabodkin, Heather McKenzie, Tyler Patchen
• 

  Goldman Sachs Closes First Life Sciences VC Fund with $650M in Equity

  The money will be funneled into early- to mid-stage therapeutic companies with “multi-asset portfolios” for the “next generation” of biotechs in addition to diagnostic and life sciences tools.

  January 3, 2024

   · 

  1 min read

   · 

  Kate Goodwin
• 

  Business

  NextGen Class of 2024: Top Life Sciences Startups to Watch This Year

  Rapport Therapeutics tops this year’s list with $250 million in Series A and B financing in just six months.

  January 3, 2024

   · 

  20 min read

   · 

  BioSpace Editorial Staff
• 

  Drug Development

  Addressing the Obesity Epidemic: The Need for New Oral Agents

  Over the past year, obesity treatments have become the focus of intense media attention and discussion in healthcare — with increased focus on Wegovy and Zepbound. This attention has highlighted the need to address the global obesity epidemic.

  January 3, 2024

   · 

  5 min read

   · 

  Jay Galeota, CEO and President, Kallyope
• 

  Deals

  Newly Launched Tome Biosciences Acquires Replace Therapeutics for $65M

  Tome Biosciences has only been on the scene for a short time but on Tuesday notched an acquisition of CRISPR-based biotech Replace Therapeutics for $65 million upfront.

  January 3, 2024

   · 

  1 min read

   · 

  Tyler Patchen
• 

  Drug Development

  Longboard Stock Skyrockets on Positive Epilepsy Data, Plans $150M Public Offering

  Patients treated with Longboard Pharmaceuticals’ bexicaserin saw a 32.5% drop in the frequency of countable motor seizures relative to placebo in a Phase 1b/IIa study. The company’s shares soared 316% Tuesday on the news.

  January 3, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Anavex’s Stock Nosedives After Posting Trial Results for Rett Syndrome

  Anavex Life Sciences’ stock dropped by more than a third in value on Tuesday after results for a Phase II/III Rett syndrome study failed to impress investors.

  January 3, 2024

   · 

  2 min read

   · 

  Tyler Patchen